Correlation between the expressions of runt-related transcription factor 2 protein and aggressiveness and metastasis of lung adenocarcinoma

doi:10.3877/cma.j.issn.2095-8773.2020.01.002

Abstract

Abstract:

Objective

To explore the expression of runt-related transcription factor 2 (Runx2) protein in lung adenocarcinoma and to investigate their relationship with aggressiveness and metastasis.

Methods

Clinical data and pathological specimens of 49 patients with lung adenocarcinoma (including lung adenocarcinoma tissues, paracancer tissues and normal lung tissues) were collected to detect the expressions of the Runx2 by immunohistochemical and Western blotting method. The correlation between the expressions of Runx2 protein and aggressiveness and metastasis were analyzed by SPSS software.

Results

The positive expression rates of Runx2 protein in lung adenocarcinoma, paracancer and normal lung tissues were 57.1%, 8.2% and 0, respectively, with statistically significant differences (P<0.001). The high expression of Runx2 protein was closely related to invasive adenocarcinoma (26/34, 76.47%), lymphnode metastasis (13/15, 86.67%), poorly differentiated (14/14, 100%), recurrence and metastasis during follow-up(8/8, 100%), and the relationship was significant (P<0.001, P=0.006, P=0.006, P=0.007, respectively).

Conclusions

The high expression of Runx2 protein in lung adenocarcinoma tissues is closely related to the low differentiation, high invasion and metastasis characteristics and recurrence of the tumor.

Key words: Lung adenocarcinoma, Runt-related transcription factor 2, Aggressiveness, Metastasis

Changming Shen, Gaofeng Qiao, Yunzeng Zhang, Feng Jin. Correlation between the expressions of runt-related transcription factor 2 protein and aggressiveness and metastasis of lung adenocarcinoma[J]. Chinese Journal of Thoracic Surgery(Electronic Edition), 2020, 07(01): 12-16.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxbwkdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-8773.2020.01.002

https://zhxbwkdzzz.cma-cmc.com.cn/EN/Y2020/V07/I01/12

Figures/Tables 4

References 19

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6)：394-424.
[2]	Yoshida B A, Sokoloff M M, Welch D R, et al. Metastasis-suppressor genes: a review and perspective on an emerging field[J]. J Natl Cancer Inst, 2000, 92(21)：1717-1730.
[3]	Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration[J]. Int J Cancer, 2015, 137(9)：2060-2071.
[4]	Akech J, Wixted J J, Bedard K, et al. Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions[J]. Oncogene, 2010, 29(6)：811-821.
[5]	Baumgart E, Cohen M S, Silva Neto B, et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors[J]. Clin Cancer Res, 2007, 13: 1685-1694.
[6]	Steeg P S. Tumor metastasis: mechanistic insights and clinical challenges[J]. Nat Med, 2006, 12(8)：895-904.
[7]	Morita K, Suzuki K, Maeda S, et al. Genetic regulation of the RUNX transcription factor family has antitumor effects[J]. J Clin Invest, 2017, 127(7)：2815-2828.
[8]	Pratap J, Lian J B, Javed A, et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone[J]. Cancer Metastasis Rev, 2006, 25(4)：589-600.
[9]	Kalluri R, Weinberg R A. The basics of epithelial-mesenchymal transition[J]. J Clin Invest, 2009, 119(6)：1420-1428.
[10]	Yang J, Zhao L, Tian W, et al. Correlation of WWOX, RUNX2 and VEGFA protein expression in human osteosarcoma[J]. BMC Med Genomics, 2013，6：56.
[11]	Baniwal S K, Khalid O, Gabet Y, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis[J]. Mol Cancer, 2010，9：258.
[12]	Ozanne B W, Spence H J, McGarry L C, et al. Transcription factors control invasion: AP-1 the first among equals[J]. Oncogene, 2007, 26: 1-10.
[13]	Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression[J]. Cancer Sci, 2010, 101(12)：2670-2675.
[14]	Yun S J, Yoon H Y, Bae S C, et al. Transcriptional repression of RUNX2 is associated with aggressive clinicopathological outcomes, whereas nuclear location of the protein is related to metastasis in prostate cancer[J]. Prostate Cancer Prostatic Dis, 2012, 15(4)：369-373.
[15]	Li H, Zhou R J, Zhang G Q, et al. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study[J]. Tumour Biol, 2013, 34(3)：1807-1812.
[16]	高鹏，沈方臻，肖文静，等．IB期非小细胞肺癌Runx2、Ezrin表达与术后转移的相关性[J]．山东大学学报(医学版)，2015，(1)：63-66.
[17]	Tandon M, Gokul K, Ali S A, et al. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B/GDF10) in lung cancer cells[J]. Mol Cancer, 2012 ，11：27.
[18]	Herreño A M, Ramírez A C, Chaparro V P, et al. Role of RUNX2 transcription factor in epithelial mesenchymal transition in non-small cell lung cancer lung cancer: Epigenetic control of the RUNX2 P1 promoter[J]. Tumour Biol, 2019，41(5)：1-13.
[19]	耿文文，蒲倩，高海东．Runx2在TGF-β1诱导的肺癌A549细胞上皮-间质转化过程中的作用研究[J]．中国癌症杂志，2019，29(9)：681-687.

项目		正常组织	癌旁组织	肺腺癌组织	χ²值	P值
Runx2表达		?	?	?	35.79	<0.001
?	高表达	0	4	28	?	?
?	阴性/低表达	49	45	21	?	?

项目		正常组织	癌旁组织	肺腺癌组织	χ²值	P值
Runx2表达		?	?	?	35.79	<0.001
?	高表达	0	4	28	?	?
?	阴性/低表达	49	45	21	?	?

临床病理参数		病例数(N＝49)	Runx2表达		P值
临床病理参数		病例数(N＝49)	阳性	阴性	P值
性别		?	?	?	0.28
?	男性	23	15	8	?
?	女性	26	13	13	?
年龄		?	?	?	0.37
?	<60岁	34	18	16	?
?	≥60岁	15	10	5	?
吸烟史		?	?	?	0.93
?	是	16	9	7	?
?	否	33	19	14	?
肿瘤直径		?	?	?	0.27
?	>3 cm	19	11	8	?
?	≤3 cm	30	17	23	?
组织学类型		?	?	?	<0.001
?	原位或微浸润腺癌	15	2	13	?
?	浸润性腺癌	34	26	8	?
分化程度(浸润)		?	?	?	0.006
?	高分化	11	5	6	?
?	中分化	9	7	2	?
?	低分化	14	14	0	?
淋巴结转移		?	?	?	0.006
?	是	15	13	2	?
?	否	34	15	19	?
随访期内复发或转移		?	?	?	0.007
?	是	8	8	0	?
?	否	41	20	21	?

临床病理参数		病例数(N＝49)	Runx2表达		P值
临床病理参数		病例数(N＝49)	阳性	阴性	P值
性别		?	?	?	0.28
?	男性	23	15	8	?
?	女性	26	13	13	?
年龄		?	?	?	0.37
?	<60岁	34	18	16	?
?	≥60岁	15	10	5	?
吸烟史		?	?	?	0.93
?	是	16	9	7	?
?	否	33	19	14	?
肿瘤直径		?	?	?	0.27
?	>3 cm	19	11	8	?
?	≤3 cm	30	17	23	?
组织学类型		?	?	?	<0.001
?	原位或微浸润腺癌	15	2	13	?
?	浸润性腺癌	34	26	8	?
分化程度(浸润)		?	?	?	0.006
?	高分化	11	5	6	?
?	中分化	9	7	2	?
?	低分化	14	14	0	?
淋巴结转移		?	?	?	0.006
?	是	15	13	2	?
?	否	34	15	19	?
随访期内复发或转移		?	?	?	0.007
?	是	8	8	0	?
?	否	41	20	21	?

Please choose a citation manager

Content to export